PPARG and ulcerative colitis: Other studies have shown that engagement of PPARγ-mediated signaling by its agonists such as rosiglitazone attenuated the severity of inflammatory lesions in both experimental and spontaneous models of colitis and might be effective in patients with ulcerative colitis [29].